Sablin Marie-Paule, Le Tourneau Christophe, El Maalouf Ghassan, Raymond Eric, Faivre Sandrine
Service inter-hospitalier de cancérologie Bichat-Beaujon, 100 boulevard du Général Leclerc, 92118 Clichy.
Bull Cancer. 2007;94 Spec No Actualites:S149-54.
Gemcitabine and pemetrexed are two novel antimetabolites with broad spectrum of antitumor activity and a safe toxicity profile. In addition, recent advances in cellular and molecular biology led to a better understanding of their mechanisms of action and resistance. Based on these latter advantages, several studies have been conducted using pemetrexed or gemcitabine either alone or with novel targeted therapies. Taken together, these recent data should result in a better and more specific use of these two very promising drugs.
吉西他滨和培美曲塞是两种新型抗代谢药物，具有广泛的抗肿瘤活性且毒性特征安全。此外，细胞生物学和分子生物学的最新进展使人们对它们的作用机制和耐药性有了更好的理解。基于这些优势，已经开展了多项单独使用培美曲塞或吉西他滨，或与新型靶向治疗联合使用的研究。综上所述，这些最新数据应能使这两种非常有前景的药物得到更好、更具针对性的应用。
